About Us
About ProMab Biotechnologies, Inc.
Founded in 2001, ProMab Biotechnologies generates and commercializes recombinant proteins, monoclonal and polyclonal antibodies, overexpression and knockout cell lines, purified primary cells, CAR-T/NK cells and mRNA-LNP through the integration of bioinformatics, gene cloning, molecular biology, protein expression/purification techniques, microbiology, immunology and novel high-throughput technologies. In addition, ProMab participates in the global biomedical research community through collaborations, partnerships, and joint ventures with other biotechnology and bio-reagent companies. ProMab also conducts contract research, focusing on CAR-T/NK cell function in vitro and in animal disease models. ProMab is on target to be one of the leading suppliers of bio-reagents in the 21st century and is committed to improving human health with a focus on the field of immunotherapy. Utilizing nearly two decades of experience generating highly specific and potent monoclonal antibodies, our success in CAR-T/NK development led us to become the first CAR-T CRO in the world.
Key Products & Services
Products
Cell Lines
Primary cells
Medium and Reagents
Services
Custom Antibody Engineering Services
Publications
HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth
Hu L, Zhang S, Sienkiewicz J, Zhou H, Berahovich R, Sun J, Li M, Ocampo A, Liu X, Huang Y, Harto H, Xu S, Golubovskaya V, Wu L. Vaccines (Basel). 2024 Jul 21; 12(7):808. doi: 10.3390/vaccines12070808
CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
Golubovskaya V, Sienkiewicz J, Sun J, Zhang S, Huang Y, Zhou H, Harto H, Xu S, Berahovich R, Wu L. Int J Mol Sci. 2023 Aug 29; 24(17):13364. doi: 10.3390/ijms241713364
Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
Wu L, Huang Y, Sienkiewicz J, Sun J, Guiang L, Li F, Yang L, Golubovskaya V. Cancers (Basel). 2022 May 20; 14(10):2518. doi: 10.3390/cancers14102518
Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
Golubovskaya V, Zhou H, Li F, Berahovich R, Sun J, Valentine M, Xu S, Harto H, Sienkiewicz J, Huang Y, Wu L. Biomedicines. 2021 Oct 9; 9(10):1422. doi: 10.3390/biomedicines9101422
PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells
Li X, Berahovich R, Zhou H, Liu X, Li F, Xu S, Wei Y, Ouaret D, Bodmer W, Wu L, Golubovskaya V. Front Biosci (Landmark Ed). 2020 Jun 1; 25(9):1765-1786. doi: 10.2741/4877
Hypoxia Selectively Impairs CAR-T Cells In Vitro
Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V, Wu L. Cancers (Basel). 2019 Apr 30; 11(5):602. doi: 10.3390/cancers11050602